Drug Profile

Research programme: anti-obesity peptides - Ablaris/University of Texas M. D. Anderson Cancer Center

Latest Information Update: 04 Nov 2017

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator University of Texas M. D. Anderson Cancer Center
Developer Ablaris Therapeutics; University of Texas M. D. Anderson Cancer Center
Class Peptides
Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

04 Nov 2017 No recent reports of development identified for preclinical development in Obesity in USA (SC, Injection)
16 Nov 2011 Preclinical development is ongoing in USA
21 Dec 2010 Preclinical trials in Obesity in USA (SC)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com